Skip to main content

menu
menu
person
Search

Interventional Cardiology

Medical & Preventive Cardiology

Lipidology & Atherosclerosis Prevention

CV RISK/DIABETES

A MULTI-SPECIALTY PERSPECTIVE

close

person

Home
Specialties
Submit A Question

Samuel Z. Goldhaber, MD

Samuel Goldhaber, MD

Program Co-Chair
Section Head, Vascular Medicine
Director, Thrombosis Research Group
Cardiovascular Medicine
Brigham and Women’s Hospital
Professor of Medicine
Harvard Medical School
Boston, MA USA

From a medical cardiologist’s perspective, why is the mandate to lower LDL-C level so important for reducing CV risk? How low do recommend lowering the LDL-C level? Where do the PCSK9 inhibitors fit into the overall sequencing strategy?

From a medical cardiologist’s perspective, why is the mandate to lower LDL-C level so important for reducing CV risk? How low do recommend lowering the LDL-C level? Where do the PCSK9 inhibitors fit into the overall sequencing strategy?

Samuel Goldhaber, MD

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

At your institution, do you experience any significant barriers to having prescriptions authorized for alirocumab or evolocumab? And how have the price reductions affected either your perception of, access to, and/or reimbursement for these agents?

Samuel Goldhaber, MD

As a thrombosis specialist and cardiologist, how do respond to the recent AHA guidelines identifying <70 mg/dL as a threshold target for high-risk patients? Is this target a starting point or a stopping point for your LDL-C lowering goals?

As a thrombosis specialist and cardiologist, how do respond to the recent AHA guidelines identifying <70 mg/dL as a threshold target for high-risk patients? Is this target a starting point or a stopping point for your LDL-C lowering goals?

Samuel Goldhaber, MD

Based on the results of ODYSSEY Outcomes and FOURIER, do you recommend that clinicians strive, in selected high-risk populations, to lower LDL-C significantly lower than 70 mg/dL?

Based on the results of ODYSSEY Outcomes and FOURIER, do you recommend that clinicians strive, in selected high-risk populations, to lower LDL-C significantly lower than 70 mg/dL?

Samuel Goldhaber, MD

Can you provide some specific examples of patients in your general cardiology practice in whom you have prescribed PCSK9 inhibitors and your rationale and the evidentiary basis for doing so? When does statin intolerance play a role?

Can you provide some specific examples of patients in your general cardiology practice in whom you have prescribed PCSK9 inhibitors and your rationale and the evidentiary basis for doing so? When does statin intolerance play a role?

Samuel Goldhaber, MD

Disclaimer:
Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

Clinical Webcasts®

Powered by BROADCASTMED